Assessing CAR-T cell therapy in vitro using patient-derived glioblastoma organoids

Tuesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Assessing CAR-T cell therapy <em>in vitro</em> using patient-derived glioblastoma organoids

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Glioblastoma is an aggressive form of brain cancer with no effective treatments currently available. Consequently, new therapeutic approaches, such as immunotherapies, are urgently needed to improve patient outcomes. While CAR-T cell therapies have shown great promise against hematological cancers, their success in solid tumors has been limited. Patient-derived tumor organoids may better recapitulate solid tumor biology and serves as a promising model for exploring the effects of new therapeutics in vitro.

This webinar will explore early efficacy signals recently demonstrated in a first-in-human, phase 1 study of dual-targeting CAR-T cells (EGFR-IL13Ra2 CAR-T cells) in patients with recurrent glioblastoma. Patient-derived glioblastoma organoids (GBOs) were treated with the same autologous CAR-T cell products received by patients in the phase 1 study, showing CAR-T cell bioactivity in vitro correlated with clinical patient metrics.

Attend this webinar to:

Discover bivalent CAR T cells targeting EGFR and IL13Ra2 showing preliminary safety and bioactivity in recurrent glioblastoma (rGBM) in a phase 1 clinical trial
Explore GBOs as a promising platform for in vitro assessment of CAR-T cell bioactivity and insights into immunotherapy efficacy
Learn how the Maestro Z live-cell analysis platform is used to evaluate the bioactivity of cell therapies against glioblastoma organoids and monolayers, label-free and in real-time

Meghan Logun

Regulatory Oncology Product Reviewer at FDA-NIH Interagency Oncology Task Force (IOTF)

Meghan Logun received her masters of science in Animal Science from Emory University and her Ph.D. in Neuroscience from the University of Georgia under the mentorship of Lohitash Karumbaiah, Ph.D., exploring the role of extracellular matrix modifications in glioblastoma invasion. She worked as a postdoctoral researcher in Donald O'Rourke's lab at the University of Pennsylvania working on creative delivery approaches for cellular immunotherapies to CNS tumors and has recently transitioned to the NIH/FDA as a postdoc and regulatory oncology product reviewer focusing on cell and gene therapies.